Diametric Capital, LP Day One Biopharmaceuticals, Inc. Transaction History
Diametric Capital, LP
- $173 Million
- Q3 2024
A detailed history of Diametric Capital, LP transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Diametric Capital, LP holds 17,723 shares of DAWN stock, worth $209,131. This represents 0.14% of its overall portfolio holdings.
Number of Shares
17,723
Previous 15,023
17.97%
Holding current value
$209,131
Previous $207,000
18.84%
% of portfolio
0.14%
Previous 0.13%
Shares
3 transactions
Others Institutions Holding DAWN
# of Institutions
178Shares Held
84MCall Options Held
144KPut Options Held
218K-
Ra Capital Management, L.P. Boston, MA7.87MShares$92.9 Million1.53% of portfolio
-
Atlas Venture Life Science Advisors, LLC6.43MShares$75.9 Million11.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.89MShares$69.5 Million0.0% of portfolio
-
Braidwell LP Stamford, CT4.87MShares$57.5 Million1.92% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$53.5 Million0.0% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $867M
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...